Our study showed that lower serum IL-6 level is found after LAG treatment, compared with the IL-6 level found after OG treatment, suggesting that LAG is a better surgical procedure in treating GC patients, in light of the adverse consequences of IL-6 mediated inflammation in GC patients. The gene discussed is IL6; the disease is gastric cancer.